Category: Uncategorized

The Phase 2 study will assess the safety and efficacy of Longeveron’s stem cell treatment under Japan’s accelerated regulatory pathway for regenerative medicine. MIAMI, June 1, 2020 /PRNewswire/ — Longeveron LLC announced today that Japan’s Pharmaceutical and Medical Devices Agency (PMDA) (the Japanese agency akin to the United States’ Food & Drug Administration) approved a Clinical Read More

MIAMI, FL – Longeveron LLC, a leading developer of adult stem cell technologies for aging-related and life-threatening conditions, announced today that it has completed enrollment in its Phase 2b Aging Frailty trial.  This double-blinded, randomized, placebo-controlled study is designed to evaluate the safety and efficacy of LMSCs in patients with mild to moderate frailty.     Read More

MIAMI, FL – Longeveron LLC, a leading developer of adult stem cell technologies for chronic, aging- related and life-threatening conditions, announced today that it has completed enrollment in its Phase 1 Alzheimer’s disease trial. This randomized, double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of LMSCs in patients with mild Alzheimer’s disease Read More

NEWS PROVIDED BY Longeveron LLC  Jan 18, 2019, 09:35 ET MIAMI, Jan. 18, 2019 /PRNewswire/ — Longeveron LLC, a biopharmaceutical company that develops cellular therapies for aging-related diseases, will play a prominent role when leading experts gather in Miami for the 2019 World Stem Cell Summit, Jan. 22-25 at the Hyatt Regency Hotel. One of the largest conferences dedicated to regenerative medicine, the Read More

NEWS PROVIDED BY Longeveron LLC  09:46 ET MIAMI, Oct. 29, 2018 /PRNewswire/ — Longeveron LLC, a biopharmaceutical company that develops cell therapies for aging-related diseases, announced that Joshua M. Hare, M.D., will be a speaker at the 2018 Maryland Technology Development Corporation (TEDCO) Entrepreneur Expo & Stem Cell Symposium, to be held October 30 at the Hotel at the University of Read More

GEN News Highlights Adult stem cell therapy developer Longeveron has won a $3.8 million NIH Small Business Innovation Research (SBIR) grant for its research toward developing stem cell therapies for aging frailty. Longeveron said it would apply the grant to the clinical research of its Mesenchymal Stem Cells (MSCs) as treatment for aging frailty, a Read More

Grant will be applied to Longeveron’s Aging Frailty stem cell research NEWS PROVIDED BY Longeveron LLC  10:17 ET SHARE THIS ARTICLE MIAMI, Oct. 18, 2018 /PRNewswire/ — Longeveron LLC, a biopharmaceutical company that develops stem cell therapies for aging-related diseases, announced that the company has been awarded a $3.8 million Small Business Innovation Research (SBIR) grant from the National Institute of Read More

Bahamas Summit Will Explore Stem Cell Innovation and Digital Health NEWS PROVIDED BY Longeveron LLC  09:40 ET MIAMI, Oct. 5, 2018 /PRNewswire/ — Longeveron LLC, a biopharmaceutical company that develops stem cell therapies, announced that Co-Founder and Chief Science Officer Joshua Hare, M.D. will be a keynote speaker at the 2018 HEALincFuture Health Innovation Summit, to be held Oct. 7-9 at the Read More

NEWS PROVIDED BY Longeveron LLC  13:33 ET MIAMI, Oct. 3, 2018 /PRNewswire/ — Longeveron LLC, a biopharmaceutical company that develops stem cell therapies for aging-related diseases, announced that the company will present at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa October 3-5 in La Jolla, California. This conference, at the Estancia La Jolla Hotel Read More

NEWS PROVIDED BY Longeveron LLC  13:18 ET MIAMI, Aug. 20, 2018 /PRNewswire/ — Longeveron LLC, a biopharmaceutical company that develops stem cell therapies for aging-related diseases, announced that the International Conference on Frailty & Sarcopenia Research (ICSFR) Task Force has published a key paper on Aging Frailty, a worldwide public health priority that is increasing in severity as Read More